tiprankstipranks
Trending News
More News >
Xeris Pharmaceuticals (XERS)
NASDAQ:XERS
Advertisement

Xeris Pharmaceuticals (XERS) Stock Statistics & Valuation Metrics

Compare
1,007 Followers

Total Valuation

Xeris Pharmaceuticals has a market cap or net worth of $847.22M. The enterprise value is $1.06B.
Market Cap$847.22M
Enterprise Value$1.06B

Share Statistics

Xeris Pharmaceuticals has 160,155,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding160,155,000
Owned by Insiders6.00%
Owned by Institutions0.28%

Financial Efficiency

Xeris Pharmaceuticals’s return on equity (ROE) is 1.85 and return on invested capital (ROIC) is -12.93%.
Return on Equity (ROE)1.85
Return on Assets (ROA)-0.17
Return on Invested Capital (ROIC)-12.93%
Return on Capital Employed (ROCE)-0.15
Revenue Per Employee515.41K
Profits Per Employee-139.18K
Employee Count394
Asset Turnover0.63
Inventory Turnover0.76

Valuation Ratios

The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.
PE Ratio
PS Ratio0.00
PB Ratio-22.65
Price to Fair Value-16.80
Price to FCF-30.48
Price to Operating Cash Flow-29.79
PEG Ratio-0.84

Income Statement

In the last 12 months, Xeris Pharmaceuticals had revenue of 203.07M and earned -54.84M in profits. Earnings per share was -0.37.
Revenue203.07M
Gross Profit166.24M
Operating Income-33.65M
Pretax Income-57.10M
Net Income-54.84M
EBITDA-11.30M
Earnings Per Share (EPS)-0.37

Cash Flow

In the last 12 months, operating cash flow was -26.71M and capital expenditures -717.00K, giving a free cash flow of -27.43M billion.
Operating Cash Flow-26.71M
Free Cash Flow-27.43M
Free Cash Flow per Share-0.17

Dividends & Yields

Xeris Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta1.23
52-Week Price Change121.01%
50-Day Moving Average4.77
200-Day Moving Average3.98
Relative Strength Index (RSI)61.80
Average Volume (3m)2.20M

Important Dates

Xeris Pharmaceuticals upcoming earnings date is Aug 6, 2025, Before Open (Confirmed).
Last Earnings DateMay 8, 2025
Next Earnings DateAug 6, 2025
Ex-Dividend Date

Financial Position

Xeris Pharmaceuticals as a current ratio of 1.67, with Debt / Equity ratio of -765.06%
Current Ratio1.67
Quick Ratio1.19
Debt to Market Cap0.47
Net Debt to EBITDA-17.68
Interest Coverage Ratio-1.01

Taxes

In the past 12 months, Xeris Pharmaceuticals has paid -2.27M in taxes.
Income Tax-2.27M
Effective Tax Rate0.04

Enterprise Valuation

Xeris Pharmaceuticals EV to EBITDA ratio is -61.69, with an EV/FCF ratio of -18.43.
EV to Sales3.43
EV to EBITDA-61.69
EV to Free Cash Flow-18.43
EV to Operating Cash Flow-18.86

Balance Sheet

Xeris Pharmaceuticals has $58.44M in cash and marketable securities with $268.75M in debt, giving a net cash position of $210.31M billion.
Cash & Marketable Securities$58.44M
Total Debt$268.75M
Net Cash$210.31M
Net Cash Per Share$1.31
Tangible Book Value Per Share-$1.03

Margins

Gross margin is 80.99%, with operating margin of -16.57%, and net profit margin of -27.00%.
Gross Margin80.99%
Operating Margin-16.57%
Pretax Margin-28.12%
Net Profit Margin-27.00%
EBITDA Margin-5.57%
EBIT Margin-13.11%

Analyst Forecast

The average price target for Xeris Pharmaceuticals is $6.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$6.00
Price Target Upside14.07% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast29.88%
EPS Growth Forecast35.11%

Scores

Smart Score10
AI Score65
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis